¡Best Of Astro este 22 y 23 de marzo de 2024!

Tu participación es crucial para hacer de este encuentro una experiencia inolvidable. ¿Cómo puedes contribuir? Además de tu presencia, te invitamos a realizar un aportación voluntaria y asegúrate de que tus pagos de anualidades estén al corriente para obtener acceso exclusivo y participar plenamente en este evento único.

$ 0



Desliza la barra para colocar el monto, por cada donación de MXN $500 pesos, te convertirás en acreedor/a a un boleto en nuestra rifa especial.

Transferencia Electrónica Inbursa
Clave Interbancaria: 036180500674500618
A nombre de: Sociedad Mexicana de Radioterapeutas AC
Concepto:Nombre del Socio

EL EVENTO COMIENZA EN:

!Comenzar Registro¡

Programa Best Of Astro

Logo
Logo
Logo
Logo
Descargar Programa Best Of Astro - Viernes
Marzo 22, 202409:00 AM
Ceremonia de inauguraciónDr Oscar Gerardo Arrieta Rodriguez & Dr Federico Maldonado Magos
Marzo 22, 202409:10 AM
Cáncer de mama
  • 09:10 AM
    Early Results of the French Multicenter, Randomized SHARE Trial Comparing Whole Breast Irradiation vs. Accelerated Partial Breast Irradiation in Postmenopausal Women with Early-Stage Breast Cancer
    Ponente(s): Dra Christian Haydee Flores Balcazar
  • 09:20 AM
    Is it the Type of Axillary Surgery or the Number of Removed Lymph Nodes That Increases the Risk of Breast Cancer Related Lymphedema (BCRL)? Results from a Prospective Screening Trial
    Ponente(s): Dra Christian Haydee Flores Balcazar
  • 09:30 AM
    Impact of Neoadjuvant Concurrent Chemoradiation (NACCRT) on Operability and Survival in Locally Advanced Inoperable Breast Cancer
    Ponente(s): Dra Christian Haydee Flores Balcazar
  • 09:40 AM
    Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women with Low-Risk DCIS after Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence (IBR) Rates
    Ponente(s): Dr Jorge Anselmo Vazquez Delgado
  • 09:50 AM
    "Long Term Outcomes of Radiation (RT)-Monotherapy vs. Combined RT + Endocrine Therapy (RT+ET) in Low-Risk Early-Stage Breast Cancer Patients 70 Years or Older after Breast-Conserving Surgery (BCS)"
    Ponente(s): Dr Jorge Anselmo Vazquez Delgado
  • 10:00 AM
    "Early Results of a Phase I Pre-Operative Single Fraction Ablative Trial for Early Stage Breast Cancer"
    Ponente(s): Dr Jorge Anselmo Vazquez Delgado
  • 10:10 AM
    Stereotactic Ablative Body Radiotherapy (SABR) for Oligoprogressive ER- Positive Breast Cancer (AVATAR): A Phase II Prospective Multicenter Trial
    Ponente(s): Dra Lorena Lio Mondragón
  • 10:20 AM
    Patient-Reported and Toxicity Results from the FABREC Study: A Multicenter Randomized Trial of Hypofractionated vs. Conventionally-Fractionated Postmastectomy Radiation Therapy After Implant-Based Reconstruction
    Ponente(s): Dra Lorena Lio Mondragón
  • 10:30 AM
    Science Highlights 1 - Breast Science Highlights
    Ponente(s): Dra Lorena Lio Mondragón
  • 10:50 AM
    Sesión preguntas y respuestas
    Ponente(s): Dra. Flores, Dra. Lio y Dr. Vazquez
Marzo 22, 202411:00 AM
Coffe BreakCoffe Break
Marzo 22, 202411:20 AM
Pediatría
  • 11:20 AM
    Outcomes Following Radiation Therapy (RT) for Very Young Age CNS Embryonal Tumors on COG ACNS0334 According to Molecular-Confirmed Diagnosis
    Ponente(s): Dra. Guadalupe García Vega.
  • 11:30 AM
    Impact of Consolidative Radiation on Overall and Progression Free Survival in Pediatric, Adolescent and Young Adult Metastatic Sarcoma
    Ponente(s): Dra. Guadalupe García Vega.
  • 11:40 AM
    High-Dose-Rate Brachytherapy for Vaginal Rhabdomyosarcoma (RMS): Lessons Learned at a Single Institution.
    Ponente(s): Dra. Beatriz García Robles.
Marzo 22, 202411:50 AM
Radiobiología
  • 11:50 AM
    Concurrent Radiation and Immunotherapy Augments Local Immunity andImproves Survival in Aneuploid NSCLC
    Ponente(s):Dra. Julia Angelina Sáenz Frías
  • 12:00 PM
    Non-Redundant Mechanisms of Immune Resistance to RadiotherapyConverge on Innate Immunity
    Ponente(s):Dra. Julia Angelina Sáenz Frías
  • 12:10 PM
    Prognostic Significance of Pretreatment Immune Cell Infiltration in MuscleInvasive Bladder Cancer Treated with Definitive Chemoradiation: Analysis of NRG RTOG 0524 and 0712
    Ponente(s): Dr Rafael Piñeiro Retiff.
  • 12:20 PM
    Neoantigen Cancer Vaccine Improves the Therapeutic Efficacy of Radiotherapy in Immunologically Cold Microsatellite-Stable Colorectal Cancer
    Ponente(s): Dr Rafael Piñeiro Retiff.
  • 12:30 PM
    Early and noninvasive PET imaging of radiation-induced lung injury by targeting CXCR4
    Ponente(s): Dr Luis Alberto Carrera Garzon.
  • 12:40 PM
    "Promoting anti-tumor immune response in ER-positive breast cancer via BET inhibition"
    Ponente(s): Dr Luis Alberto Carrera Garzon.
Marzo 22, 202412:50 PM
Ivestigacion sobre servicios de salud (Cuidados paliativos)
  • 12:50 PM
    Radiotherapy Resources in Latin America and the Caribbean: An International Atomic Energy Agency Analysis of Current and Projected Needs
    Ponente(s): Dr. Luis Alberto Contreras Contreras
  • 01:00 PM
    Unplanned Hospitalization and Subsequent Mortality in Lung Cancer Patients Undergoing Concomitant Chemo-/Immuno-Therapy and Radiotherapy: An Analysis of Over 10,000 Patients in a Nationwide Database
    Ponente(s): Dr. Luis Alberto Contreras Contreras
  • 01:10 PM
    Polymetastatic Recurrence-Free Survival in Patients with Repeat Oligometastases on the SABR-5 Trial
    Ponente(s): Dr Ulises Mejia Gamboa
  • 01:20 PM
    Diagnostic CT-Enabled Radiation Therapy (DART): Results of a Randomized Trial for Palliative Radiation Therapy.
    Ponente(s): Dr Ulises Mejia Gamboa
  • 01:30 PM
    Sesión preguntas y respuestas
    Ponente(s): Dra Garcia, Dra Garcia, Dr León, Dr Piñeiro, Dr Garzon, Dr Contreras, Dr Mejia
Marzo 22, 202401:50 PM
ComidaComida
Marzo 22, 202403:20 PM
Cabeza y cuello
  • 03:20 PM
    A Phase II Trial Evaluating Rapid Mid-Treatment Nodal Shrinkage to Select for Adaptive Deescalation in p16+ Oropharyngeal Cancer Patients Undergoing Definitive Chemoradiation
    Ponente(s): Dra Cristina Rodriguez Acosta
  • 03:30 PM
    Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin- Ineligible Locally Advanced HNSCC Patients: Final Results of a Phase I Trial
    Ponente(s): Dra Cristina Rodriguez Acosta
  • 03:40 PM
    SBRT in 3 Fractions for T1 Glottic Cancer
    Ponente(s): Dra. Daneli Ruiz Sánchez
  • 03:50 PM
    Involved Site Radiotherapy in HPV Positive Oropharyngeal Cancer: Patterns of Failure Analysis Across Prospective De-Escalation Trials
    Ponente(s): Dra. Daneli Ruiz Sánchez
  • 04:00 PM
    "Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920"
    Ponente(s): Dr Germán Chávez Tahuilán
  • 04:10 PM
    Acute Toxicity and Efficiency Outcomes in the DARTBOARD Randomized Trial of Daily Adaptive Radiotherapy for Head and Neck Squamous Cell Carcinoma
    Ponente(s): Dr Germán Chávez Tahuilán
  • 04:20 PM
    Randomized Controlled Trial of Hypofractionated vs. Normo-fractionated Accelerated Radiation Therapy with or without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO)
    Ponente(s): Dr Samuel Rosales Pérez
  • 04:30 PM
    A prospective study evaluating health
    Ponente(s): Dr Samuel Rosales Pérez
  • 04:40 PM
    Science Highlights 3 - Head and Neck Science Highlights 2023 - Thomas Galloway MD
    Ponente(s): Dr Samuel Rosales Pérez
Marzo 22, 202405:00 PM
Pulmon
  • 05:00 PM
    "High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial"
    Ponente(s): Dr. Pedro Rubén León Arceo
  • 05:10 PM
    30 Gy vs. 45 Gy Consolidative Thoracic Radiation (cTRT) for Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Multicenter, Randomized, Phase 3 Trial
    Ponente(s): Dr. Pedro Rubén León Arceo
  • 05:20 PM
    Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial
    Ponente(s): Dr Adolfo Fernández Díaz
  • 05:30 PM
    "Adaptive Radiotherapy Guided by PET/CT in Patients with Locally Advanced Non–Small Cell Lung Cancer: A Phase II Randomized Study"
    Ponente(s): Dr Adolfo Fernández Díaz
  • 05:40 PM
    "Primary Endpoint Results of NRG CC003: Phase IIR/III Trial of Prophylactic Cranial Irradiation (PCI) with or without Hippocampal Avoidance (HA) for Small Cell Lung Cancer (SCLC)"
    Ponente(s): Dr. Miguel Angel Souto Del Bosque
  • 05:50 PM
    "Stereotactic Radiotherapy vs. Whole Brain Radiation Therapy for Patients with 1-10 Brain Metastases from Small Cell Lung Cancer: Results of the Randomized ENCEPHALON (ARO 2018-9) Trial"
    Ponente(s): Dr. Miguel Angel Souto Del Bosque
  • 06:00 PM
    Science Highlights 3 - SH 06 - Science Highlights 6 - Lung Cancer/Thoracic Malignancies
    Ponente(s): Dr. Miguel Angel Souto Del Bosque
  • 06:20 PM
    Sesión preguntas y respuestas
    Ponente(s): Dra Rodriguez, Dra Danieli, Dr Chavez, Dr Rosales, Dra Saenz, Dr Adolfo, Dr Souto
Marzo 22, 202406:30 PM
ASAMBLEA GENERAL EXTRAORDINARIA DE SOCIOSASAMBLEA GENERAL EXTRAORDINARIA DE SOCIOS
Descargar Programa Best Of Astro - Sabado
Marzo 23, 202408:00 AM
SNC
  • 08:00 AM
    Radiotherapy for Metastatic Spinal Cord Compression with Increased Doses: Final Results of the RAMSES-01 Trial
    Ponente(s): "Dr. Pablo Moo Chable "
  • 08:10 AM
    Efficacy and Toxicity of Different Target Volume Delineations of Radiotherapy Based on the Updated RTOG/NRG and EORTC Guidelines in Patients with High Grade Glioma: A Randomized, Controlled Clinical Trial
    Ponente(s): "Dr. Pablo Moo Chable "
  • 08:20 AM
    Results of a Phase I Trial of Dose Escalation for Preoperative Stereotactic Radiosurgery for Patients with Large Brain Metastases
    Ponente(s): "Dr. Pablo Moo Chable "
  • 08:30 AM
    Stereotactic Radiosurgery for 1-10 Brain Metastases avoids Whole-Brain Radiotherapy - Results of the CYBER-SPACE Randomized Phase 2 Trial
    Ponente(s): Dr Alejandro Rodríguez Camacho
  • 08:40 AM
    Hypofractionated Stereotactic Radiotherapy (HFSRT) of the Resection Cavity versus Whole-Brain Radiotherapy (WBRT) following Brain Metastasis Resection – Results of the ESTRON Randomized Phase 2 Trial
    Ponente(s): Dr Alejandro Rodríguez Camacho
  • 08:50 AM
    Science Highlights 4 - CNS Science Highlights
    Ponente(s): Dr Alejandro Rodríguez Camacho
  • 09:10 AM
    Sesión preguntas y respuestas
    Ponente(s): Dr. Pablo Moo Chable y Dr Alejandro Rodríguez Camacho
Marzo 23, 202409:20 AM
Sarcomas
  • 09:20 AM
    Meta-Analysis of Five Fraction Preoperative Radiotherapy for Soft TissueSarcoma
    Ponente(s): Dr Adriel García Carro
  • 09:30 AM
    Hypofractionated Accelerated Radiation Dose-Painting (HARD) Improves Local Control in Unresected Soft-Tissue Sarcoma
    Ponente(s): Dr Adriel García Carro
Marzo 23, 202409:40 AM
Informática
  • 09:40 AM
    A Prospective Study of Machine Learning-Assisted Radiotherapy Planning for Patients Receiving 54 Gy to the Brain
    Ponente(s): Dra. María Yicel Bautista Hernández
  • 09:50 AM
    Dynamic Prediction of Toxicities in Head and Neck Cancer Radiotherapy by 3D Convolutional Neural Network Using Daily Cone-Beam CTs
    Ponente(s): Dra. María Yicel Bautista Hernández
  • 10:00 AM
    Operational Ontology for Radiation Oncology (OORO): A Professional Society- Based, Multi-Stakeholder Consensus Driven Informatics Standard Supporting Clinical and Research Use of Real-World Data
    Ponente(s): Dra Angelica Carolina Sandoval Méndez
  • 10:10 AM
    Deep Learning for Automatic Prediction of Lymph Node Station Metastasis in Esophageal Cancer Patients from Contrast-Enhanced CT
    Ponente(s): Dra Angelica Carolina Sandoval Méndez
  • 10:20 AM
    Sesión preguntas y respuestas
    Ponente(s): Dr Adriel Garcia, Dra Yisel Bautista y Dra Angelica Sandoval
Marzo 23, 202410:30 AM
Coffe BreakCoffe Break
Marzo 23, 202410:50 AM
Hemato
  • 10:50 AM
    Radiotherapy in Young, High-Risk Patients with Aggressive B-cell Lymphoma:Long-Term Results from the Open-Label, Randomized, Phase 3 R-MegaCHOEP Trial
    Ponente(s): Dra. Yael Cázares Ordoñez
  • 11:00 AM
    Phase II Multi-Institutional Study of a Low-Dose (4Gy) Palliative Response- Adapted Radiotherapy Regimen for Symptomatic Bone Metastases from Multiple Myeloma: Planned Interim Analysis of First 40 Patients
    Ponente(s): Dra. Yael Cázares Ordoñez
  • 11:10 AM
    Consolidative Radiotherapy in Place of Autologous Stem Cell Transplant in Patients with Low-Risk Relapsed/Refractory (R/R) Classic Hodgkin Lymphoma (cHL) Treated with Nivolumab plus Brentuximab Vedotin: CheckMate 744
    Ponente(s): Dra. Yael Cázares Ordoñez
  • 11:20 AM
    Management and Outcomes of Hodgkin Lymphoma Patients Who Achieve Partial Metabolic Response on PET Scans Post-Chemotherapy
    Ponente(s): Dra. Diana Vanesa Toledano Cuevas
  • 11:30 AM
    Phase I Trial of ‘Re-Priming’ Radiation Therapy for Relapsed/Refractory Non- Hodgkin Lymphoma Patients in Incomplete Response after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
    Ponente(s): Dra. Diana Vanesa Toledano Cuevas
  • 11:40 AM
    73_Consolidative Radiotherapy for Residual PET-Avid_54257
    Ponente(s): Dra. Diana Vanesa Toledano Cuevas
  • 12:00 PM
    Sesión preguntas y respuestas
    Ponente(s): Dra Yael Cazares y Dra Diana T
Marzo 23, 202412:10 PM
Gastro
  • 12:10 PM
    Relationships between Microbiome and Response to NeoadjuvantChemoradiotherapy in Rectal Cancer
    Ponente(s): Dr. José Hinojosa Gómez
  • 12:20 PM
    Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-Gastric Diseases (PROCEED): Assessment of Pathologic Response in a Prospective, Phase II Single-Arm Trial
    Ponente(s): Dr. José Hinojosa Gómez
  • 12:30 PM
    Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma: A Randomized Phase II Clinical Trial
    Ponente(s): Dr. Melchor Armando Vázquez Uc
  • 12:40 PM
    Prognostic Role and Time Varying Failure Hazard of Neoadjuvant Rectal (NAR) Scores in the Stellar Randomized Phase 3 Trial
    Ponente(s): Dr. Melchor Armando Vázquez Uc
  • 12:50 PM
    Science Highlights 7 - GI Science Highlights - Understanding Toxicities, Optimizing Dose, and CROSSing the Threshold for Immune Therapy
    Ponente(s): Dr. Melchor Armando Vázquez Uc
  • 01:10 PM
    Sesión preguntas y respuestas
    Ponente(s): Dr. José Hinojosa Gómez y Dr. Melchor Armando Vázquez Uc
Marzo 23, 202401:20 PM
ComidaComida
Marzo 23, 202402:40 PM
Gine
  • 02:40 PM
    Clinical Validation of HPV ctDNA for Early Detection of Residual Disease Following Chemoradiation in Cervical Cancer
    Ponente(s): Dra. Cindy Sharon Ortiz Arce
  • 02:50 PM
    Association between Regular Vaginal Dilation and/or Sexual Activity and Long- Term Vaginal Morbidity in Cervical Cancer Survivors
    Ponente(s): Dra. Cindy Sharon Ortiz Arce
  • 03:00 PM
    HPV Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation
    Ponente(s): Dra. Cindy Sharon Ortiz Arce
  • 03:10 PM
    Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer: Primary Endpoint Results of the SAVE Randomized Clinical Trial
    Ponente(s): Dra Dharely Raquel Cid Sánchez
  • 03:20 PM
    HYPOCx-iRex (TCTR20210812003) A Phase II RCT: 44Gy/20F VS 45Gy/25F CCRT in Cervical Cancer – 6-mo Post-RT Update
    Ponente(s): Dra Dharely Raquel Cid Sánchez
  • 03:30 PM
    Sesión preguntas y respuestas
    Ponente(s): Dra Cindy Sharon Ortiz Arce y Dra Dharely
Marzo 23, 202403:40 PM
Urología
  • 03:40 PM
    Health-Related Quality of Life at Five Years for a Randomized Trial of Tri-Modality Therapy with I-125 Brachytherapy, External Beam Radiation Therapy, and Short- vs. Long-Term Androgen Deprivation Therapy for High- Risk Localized Prostate Cancer (TRIP)
    Ponente(s): Dr Daniel Rivera Sánchez
  • 03:50 PM
    Long-Term Outcomes of NRG/RTOG 0126, a Randomized Trial of High Dose (79.2Gy) vs. Standard Dose (70.2Gy) Radiation Therapy (RT) for Men with Localized Prostate Cancer
    Ponente(s): Dr Daniel Rivera Sánchez
  • 04:00 PM
    Long-Term Follow-Up Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Non-Inferiority Study Comparing Two Fractionation Schedules in Patients with Favorable-Risk Prostate Cancer
    Ponente(s): Dr Daniel Rivera Sánchez
  • 04:10 PM
    Quality of Life Results of Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy: NRG Oncology/RTOG 0534 SPPORT
    Ponente(s): Dr. Jorge Miguel Jiménez López.
  • 04:20 PM
    TROG 15.03/ANZUP International Multicenter Phase II Trial of Focal Ablative STereotactic RAdiotherapy for Cancers of the Kidney (FASTRACK II)
    Ponente(s): Dr. Jorge Miguel Jiménez López.
  • 04:30 PM
    Final Analysis of a Phase III Controlled Randomized Study of Stereotactic Body Proton Therapy or Conventionally Fractionated Proton Therapy for Early Prostate Cancer: PCG GU002
    Ponente(s): Dr. Jorge Miguel Jiménez López.
  • 04:40 PM
    Final Results from a Prospective Randomized Pilot Trial of Stereotactic Body Radiation Therapy vs. Radiofrequency Ablation for the Management of Small Renal Masses (RADSTER
    Ponente(s): Dr. Felipe De Jesús Tallabs Villafaña
  • 04:50 PM
    FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy (SRT) and 6 Months of GnRH Agonist with Either Bicalutamide or Abiraterone Acetate/Prednisone (AAP) and Apalutamide (Apa) Post-Radical Prostatectomy (RP).
    Ponente(s): Dr. Felipe De Jesús Tallabs Villafaña
  • 05:00 PM
    Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer
    Ponente(s): Alejandro Villalvazo Anaya
  • 05:10 PM
    Science Highlights 8 - GU Science Highlights
    Ponente(s):Dr. Alejandro Villalvazo Anaya
  • 05:30 PM
    Sesión preguntas y respuestas
    Ponente(s):Dr. Daniel Rivera, Dr jimenez, Dr Tallabs, Dr Villalvazo
Marzo 23, 202405:40 PM
CLAUSURA DEL EVENTODr Federico Maldonado Magos
WhatsApp